Skip to content
value.today

Avidity Biosciences LLC

🇺🇸 La Jolla, California, USABiotechnologyFounded 2012
Total raised
$519 M
3 rounds on record
Latest round
$400 M
Mar 2024
First round on record
Dec 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Avidity Biosciences LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$400 MNo. 3$250 million to $1 billion

Avidity Biosciences LLC: Raise no. 3, Mar 2024

Investors in this round

45 investors had bought by the notice of Mar 19, 2024: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Avidity Biosciences LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$400 M of $400 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$20,010,438
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Levin · Executive Officer
  • Michael Michael MacLean · Executive Officer
  • Sarah Boyce · Executive Officer, Director
  • Teresa Michael McCarthy · Executive Officer
  • W. Michael Flanagan · Executive Officer
  • Carsten Michael Boess · Director
  • Edward Michael Kaye · Director
  • Jean Michael Kim · Director
  • Noreen Michael Henig · Director
  • Tamar Michael Thompson · Director
  • Troy Michael Wilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets, LLC (CRD 120128) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KY, MA, MD, MI, MN, NC, ND, NH, NJ, NV, NY, OH, OK, OR, PA, PR, RI, SC, TX, UT, VA, VT, WA, WI
  • BofA Securities Inc. (CRD 283942) · Charlotte, North CarolinaSold in all US states
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The compensation payable to the placement agents under the total offering amount is estimated to consist of a cash fee of 5.0% of the total amount sold in Item 13, allocated among the placement agents.”

Signed by Michael MacLean, Chief Financial and Business Officer. Source: SEC Form D, newest notice filed Mar 19, 2024. Read the notice at the SEC.

equity, optionsSEC
Nov 2019$101 MNo. 2$50 to $250 million

Avidity Biosciences LLC: Raise no. 2, Nov 2019

Investors in this round

28 investors had bought by the notice of Nov 13, 2019: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Avidity Biosciences LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$101 M of $104 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Preferred Stock upon conversion of promissory notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,698,797
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sarah Boyce · Executive Officer, Director
  • Edward Kaye · Director
  • Michael Martin · Director
  • Noreen Henig · Director
  • Roderick Wong · Director
  • Todd Brady · Director
  • Troy Wilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SVB Leerink LLC (CRD 39011) · New York, New YorkSold in CA, CO, CT, IL, MA, MD, NY, and outside the US

Remarks in the notice

  • On the amounts: “Total Amount Sold above also includes conversion of promissory notes (principal and interest).”

Signed by Sarah Boyce, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 13, 2019. Read the notice at the SEC.

equitySEC
Dec 2016$18 MNo. 1$10 to $50 million

Avidity Biosciences LLC: Raise no. 1, Dec 2016

Investors in this round

21 investors had bought by the notice of Jan 6, 2017: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Avidity Biosciences LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $23 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Units (including conversion of promissory notes)
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • P. Kent Hawryluk · Executive Officer
  • Troy Wilson PhD., JD · Executive Officer, Director
  • Michael Martin PhD. · Director
  • Todd Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series B Preferred Units”

Signed by P. Kent Hawryluk, Chief Business Officer. Source: SEC Form D, newest notice filed Jan 6, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Avidity Biosciences LLC chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2024

That is all the official record says: Avidity Biosciences LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Avidity Biosciences LLC
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Private Healthcare Fund II, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Lilly Eli & CoOthernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
RTW Investments, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Avidity Biosciences LLC
NameRoleNamed in
Arthur LevinExecutive officerMar 2024
Michael Michael MacLeanExecutive officerMar 2024
Sarah BoyceExecutive officerMar 2024
Teresa Michael McCarthyExecutive officerMar 2024
W. Michael FlanaganExecutive officerMar 2024
P. Kent HawrylukExecutive officerJan 2017
Troy Wilson PhD., JDExecutive officerJan 2017
Carsten Michael BoessDirectorMar 2024
Edward Michael KayeDirectorMar 2024
Jean Michael KimDirectorMar 2024
Noreen Michael HenigDirectorMar 2024
Sarah BoyceDirectorMar 2024
Tamar Michael ThompsonDirectorMar 2024
Troy Michael WilsonDirectorMar 2024
Edward KayeDirectorNov 2019
Michael MartinDirectorNov 2019
Noreen HenigDirectorNov 2019
Roderick WongDirectorNov 2019
Todd BradyDirectorNov 2019
Troy WilsonDirectorNov 2019
Michael Martin PhD.DirectorJan 2017
Troy Wilson PhD., JDDirectorJan 2017